[go: up one dir, main page]

NL1022442C2 - Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen. - Google Patents

Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen. Download PDF

Info

Publication number
NL1022442C2
NL1022442C2 NL1022442A NL1022442A NL1022442C2 NL 1022442 C2 NL1022442 C2 NL 1022442C2 NL 1022442 A NL1022442 A NL 1022442A NL 1022442 A NL1022442 A NL 1022442A NL 1022442 C2 NL1022442 C2 NL 1022442C2
Authority
NL
Netherlands
Prior art keywords
nutrients
lipid
pharmaceutically
absorption
improve
Prior art date
Application number
NL1022442A
Other languages
English (en)
Inventor
Willem Ferdinand Nieuwenhuizen
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL1022442A priority Critical patent/NL1022442C2/nl
Application filed by Tno filed Critical Tno
Priority to EP04703544A priority patent/EP1585508B1/en
Priority to PCT/NL2004/000047 priority patent/WO2004064847A1/en
Priority to US10/542,845 priority patent/US7968529B2/en
Priority to JP2006500734A priority patent/JP2006516279A/ja
Priority to PCT/NL2004/000048 priority patent/WO2004064820A2/en
Priority to DE602004020316T priority patent/DE602004020316D1/de
Priority to US10/542,709 priority patent/US20060128666A1/en
Priority to JP2006500735A priority patent/JP2006516280A/ja
Priority to ES04703544T priority patent/ES2325260T3/es
Priority to EP04703545A priority patent/EP1585528A1/en
Priority to AT04703544T priority patent/ATE427106T1/de
Application granted granted Critical
Publication of NL1022442C2 publication Critical patent/NL1022442C2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NL1022442A 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen. NL1022442C2 (nl)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NL1022442A NL1022442C2 (nl) 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
PCT/NL2004/000047 WO2004064847A1 (en) 2003-01-20 2004-01-20 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers
US10/542,845 US7968529B2 (en) 2003-01-20 2004-01-20 Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
JP2006500734A JP2006516279A (ja) 2003-01-20 2004-01-20 吸収促進剤としてスフィンゴミエリン及びリソスフィンゴミエリンを使用する方法
EP04703544A EP1585508B1 (en) 2003-01-20 2004-01-20 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
PCT/NL2004/000048 WO2004064820A2 (en) 2003-01-20 2004-01-20 Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
DE602004020316T DE602004020316D1 (de) 2003-01-20 2004-01-20 Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
US10/542,709 US20060128666A1 (en) 2003-01-20 2004-01-20 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers
JP2006500735A JP2006516280A (ja) 2003-01-20 2004-01-20 血漿コレステロール及びトリアシルグリセロールレベルを減少するためにスフィンゴ脂質を使用する方法
ES04703544T ES2325260T3 (es) 2003-01-20 2004-01-20 Utilizacion de esfingolipidos para reducir los niveles de triacilglicerol y colesterol en el plasma.
EP04703545A EP1585528A1 (en) 2003-01-20 2004-01-20 Use of sphingomyelin and lyso-sphingomyelin as absorption enhancers
AT04703544T ATE427106T1 (de) 2003-01-20 2004-01-20 Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL1022442A NL1022442C2 (nl) 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.

Publications (1)

Publication Number Publication Date
NL1022442C2 true NL1022442C2 (nl) 2004-07-22

Family

ID=32768714

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1022442A NL1022442C2 (nl) 2003-01-20 2003-01-20 Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.

Country Status (5)

Country Link
US (1) US20060128666A1 (nl)
EP (1) EP1585528A1 (nl)
JP (1) JP2006516279A (nl)
NL (1) NL1022442C2 (nl)
WO (1) WO2004064847A1 (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005281257A (ja) * 2004-03-30 2005-10-13 Snow Brand Milk Prod Co Ltd 美肌剤
KR101442047B1 (ko) 2005-09-22 2014-09-18 유키지루시 메그밀크 가부시키가이샤 스핑고미엘린 함유 의약, 음식품 또는 사료
NZ571807A (en) * 2006-04-07 2013-05-31 Megmilk Snow Brand Co Ltd Fat accumulation inhibitor
JP2008074785A (ja) * 2006-09-22 2008-04-03 Asahi Breweries Ltd 脳機能改善組成物
WO2009066685A1 (ja) * 2007-11-19 2009-05-28 Snow Brand Milk Products Co., Ltd. 感覚改善剤
JP2016013083A (ja) * 2014-07-01 2016-01-28 花王株式会社 麺つゆ

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009163A1 (en) * 1987-05-22 1988-12-01 Danbiosyst U.K. Limited Enhanced uptake drug delivery system
EP0609078A1 (en) * 1993-01-27 1994-08-03 Scotia Holdings Plc Formulations containing unsaturated fatty acids
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
JPH11269074A (ja) * 1998-03-18 1999-10-05 Snow Brand Milk Prod Co Ltd 脂質の消化吸収機能改善剤
WO2000007577A2 (de) * 1998-08-06 2000-02-17 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
JP2000350563A (ja) * 1999-06-10 2000-12-19 Snow Brand Milk Prod Co Ltd 乳幼児用栄養組成物
KR20010026759A (ko) * 1999-09-08 2001-04-06 유병서 인지질이 첨가된 배합사료
WO2001082897A2 (en) * 2000-05-02 2001-11-08 Enzrel, Inc. Liposome drug delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492259A1 (fr) * 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5714478A (en) * 1995-09-29 1998-02-03 Spiegel; Sarah Sphingosylphosphorylcholine as a wound-healing agent
JP3868052B2 (ja) * 1997-03-18 2007-01-17 タカラバイオ株式会社 スフィンゴ脂質セラミドｎ−デアシラーゼ

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009163A1 (en) * 1987-05-22 1988-12-01 Danbiosyst U.K. Limited Enhanced uptake drug delivery system
EP0609078A1 (en) * 1993-01-27 1994-08-03 Scotia Holdings Plc Formulations containing unsaturated fatty acids
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
JPH11269074A (ja) * 1998-03-18 1999-10-05 Snow Brand Milk Prod Co Ltd 脂質の消化吸収機能改善剤
WO2000007577A2 (de) * 1998-08-06 2000-02-17 Wolfgang Stremmel Phosphatidylcholin als arzneimittel mit schleimhautschützender wirkung
JP2000350563A (ja) * 1999-06-10 2000-12-19 Snow Brand Milk Prod Co Ltd 乳幼児用栄養組成物
KR20010026759A (ko) * 1999-09-08 2001-04-06 유병서 인지질이 첨가된 배합사료
WO2001082897A2 (en) * 2000-05-02 2001-11-08 Enzrel, Inc. Liposome drug delivery

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BISCHOFF ANGELA ET AL: "Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 130, no. 8, August 2000 (2000-08-01), pages 1871 - 1877, XP008021723, ISSN: 0007-1188 *
BRONDSTED HELLE ET AL: "Drug delivery studies in Caco-2 monolayers: III. Intestinal transport of various vasopressin analogues in the presence of lysophosphatidylcholine.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 114, no. 2, 1995, pages 151 - 157, XP001166873, ISSN: 0378-5173 *
DATABASE WPI Section Ch Week 200002, Derwent World Patents Index; Class B05, AN 2000-016496, XP002254314 *
DATABASE WPI Section Ch Week 200128, Derwent World Patents Index; Class B04, AN 2001-268278, XP002254313 *
DATABASE WPI Section Ch Week 200158, Derwent World Patents Index; Class D13, AN 2001-528175, XP002254312 *
ELKHESHEN, S. A. ET AL: "Enhancement of dissolution and bioavailability of piroxicam via solid dispersion with phospholipids", BULLETIN OF THE FACULTY OF PHARMACY (CAIRO UNIVERSITY) (2001), 39(1), 309-320, XP001166877 *
HOVGAARD, L., ET AL.: "Drug delivery studies in Caco-2 monolayers. II. Absorpton enhancer effects of lysophosphatidylcholines.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 114, 1995, pages 141 - 149, XP001166867 *
LO, YU-LI: "Phospholipids as Multidrug Restistance Modulators of the Transport of Epirubicin in Human Inzestinal Epithelial Caco-2 Cell Layers and Everted Gut Sacs of Rats.", BIOCHEMICAL PHARMACOLOGY, vol. 60, no. 9, 2000, pages 1381 - 1390, XP001166868 *
SAWAI T ET AL: "The effect of phospholipids and fatty acids on tight-junction permeability and bacterial translocation.", PEDIATRIC SURGERY INTERNATIONAL. GERMANY MAY 2001, vol. 17, no. 4, May 2001 (2001-05-01), pages 269 - 274, XP001166871, ISSN: 0179-0358 *
SCHMELZ E M ET AL: "Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: Implications for dietary sphingolipids and colon carcinogenesis", CANCER RESEARCH 1996 UNITED STATES, vol. 56, no. 21, 1996, pages 4936 - 4941, XP008021439, ISSN: 0008-5472 *
VIOLA GIAMPIETRO ET AL: "Absorption and distribution of arachidonate in rats receiving lysophospholipids by oral route.", JOURNAL OF LIPID RESEARCH, vol. 34, no. 11, 1993, pages 1843 - 1852, XP001166872, ISSN: 0022-2275 *

Also Published As

Publication number Publication date
EP1585528A1 (en) 2005-10-19
US20060128666A1 (en) 2006-06-15
JP2006516279A (ja) 2006-06-29
WO2004064847A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
CY2016031I1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
DK1480615T3 (da) Superfin formoterolformulering
WO2002028999A3 (en) Gene expression profiles in granulocytic cells
WO2006015263A3 (en) Lonidamine analogs
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
ZA200507346B (en) Topical formulation of ivermectin for the treatment of dermatological conditions
IS7571A (is) Ný lífeðlisfræðilega virk efni
ITMI20020189A0 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
DE60136909D1 (de) Arzneimittel mit anemonin als aktivum zur behandlung von aseptischer inflammation
EA200702496A1 (ru) Местная композиция, содержащая желатин
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
AU2003303678A1 (en) Urea derivatives and their use as anti-inflammatory agents
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
FI20031927A0 (fi) Terapeuttisesti vaikuttavia aineita ja niiden käyttö
ITMI20021860A1 (it) Impiego dei triptani come agenti antivirali.
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
DE60323874D1 (de) Formulierung zur rektalen verabreichung thrombolytischer wirkstoffe
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
DE502004001936D1 (de) Herstellung von Saccharidestern

Legal Events

Date Code Title Description
PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20090801